Amarin Corporation plc (the “Company”) has established a
website, https://www.voteamarin.com/, to communicate
with the Company’s shareholders regarding its solicitation of
proxies from shareholders at the Company’s 2023 Special General
Meeting of Shareholders. Below are press releases issued by the
Company and other communication released on February 16, 2023,
which are posted to such website. The Company has filed a
definitive proxy statement (DEFC14A) and WHITE proxy card with the
U.S. Securities and Exchange Commission in connection with its
solicitation of proxies from shareholders. Shareholders are
strongly encouraged to read such proxy statement and accompanying
WHITE proxy card as they contain important information.
The following is a press release issued by the Company:
Amarin Clearly and Definitively Instructed
Registrar to Accept ALL Submitted Proxy Cards
Sarissa Issued its False Release Hours After
Receiving Confirmation That All Proxy Cards Were Being
Accepted
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 16, 2023 (GLOBE
NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the
“Company”) today corrected the record regarding the latest
misinformation from Sarissa Capital Management (“Sarissa”).
Contrary to Sarissa’s press release, Amarin clearly and
definitively instructed its registrar to accept ALL submitted proxy
cards, including both blue and white cards, with regard to its
upcoming General Meeting of Shareholders. This is standard practice
for a contested solicitation process and was established before the
proxy solicitation process even began. The idea that a company
registrar would only accept one set of proxy cards is categorically
false.
This is yet another example of Sarissa’s focus on advancing its own
interests at the expense of all Amarin shareholders. The registrar
confirmed that it notified Sarissa eight hours in advance of their
press release that all proxy cards were being considered. It is
clear that Sarissa is willing to say anything in an attempt to get
on the Board.
In a note dated February 16, 2023, from the registrar:
“As mentioned, [the registrar] did not advise [Sarissa] that
Amarin were not accepting these proxy cards. As this was a
different proxy form that [the registrar] had seen before, we had
to check with Amarin if we were to accept it. Amarin advised that
we were able to accept therefore we have lodged the votes.”
As this confirmation shows, the registrar was clearly instructed to
accept all proxy cards, including Sarissa’s blue proxy card.
Materials regarding the Board of Directors’ recommendations for the
General Meeting can be found at www.voteamarin.com.
About Amarin
Amarin is an innovative pharmaceutical company leading a new
paradigm in cardiovascular disease management. From our foundation
in scientific research to our focus on clinical trials, and now our
commercial expansion, we are evolving and growing rapidly. Amarin
has offices in Bridgewater, New Jersey in the United States, Dublin
in Ireland, Zug in Switzerland, and other countries in Europe as
well as commercial partners and suppliers around the world. We are
committed to increasing the scientific understanding of the
cardiovascular risk that persists beyond traditional therapies and
advancing the treatment of that risk.